1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Slides:

Advertisements

Similar presentations

A Study of Caffeine The negative effects of caffeine are sufficient enough that individuals should limit their consumption.

Advertisements

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Objectives Define urinary incontinence

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

CHANTIX (varenicline tartrate ) ROBERT A. SCHWARTZ Executive Vice President Managing Attorney - Houston Attorney in Charge of Mass Tort and Commercial.

Special Topics in IND Regulation

Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 11 Antianxiety Agents.

Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.

Urinary Incontinence Dr Asso F.A.Amin MRCP(UK),MRCGP,MRCPE.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

And Alzheimer’s Disease

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post-Pediatric Exclusivity Postmarketing Adverse Event Review SERTRALINE ( Zoloft) Dr. Solomon Iyasu Medical Team Leader Division of Pediatric.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

GERIATRICS : UI Dr. Meg-angela Christi Amores. URINARY INCONTINENCE  major problem for older adults, afflicting up to 30% of community-dwelling elders.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Jeffrey Jonas, MD Vice President CNS - Forest Research Institute Citalopram and Escitalopram Pediatric Safety Data.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Buspar And Marijuana Cheap Buspar Meds buspirone for panic attacks taking ativan with buspar buspar for social phobia how long does dizziness last with.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

1 Regulatory Background on Antidepressants and Suicidality in Pediatric Patients Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division.

1 門診案例討論 ~ Methylphenidate Use in Narcolepsy 藥師 : 郭子瑋日期 :

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

Presentation transcript:

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate Director Pediatric and Maternal Health Staff Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Drug: Ditropan ® (oxybutynin) Therapeutic Category: Antispasmodic Sponsor: Johnson and Johnson Original Market Approval: July 16, 1975 Pediatric Exclusivity Granted: February 8, 2002 Mechanism of action: Anticholiniergic

3 Background Drug Information Indication: –Adults : symptoms of bladder irritability associated with voiding in patients with uninhibited neurogenic bladder (urgency, frequency, urinary leakage, urge incontinence, dysuria) –Children: >5 years and XL in >6 years for detrusor muscle over-activity in association with a neurological condition (e.g.. Spina bifida). Pediatric Dosage: –5 mg twice daily with maximum 5 mg three times daily

4 Oxybutynin: Pediatric Labeling Changes Ditropan –Additional information on dose and PK parameters –Precautions section of label updated Ditropan XL –Safety and effectiveness established down to 6 years of age

5 Oxybutynin : Pediatric Adverse Events 5 unduplicated reports during the one year post exclusivity period (2/8/02-3/19/03) –Too few reports to make an assessment 10 additional unduplicated reports during the subsequent three year period (3/19/03- 8/30/06) Total since exclusivity granted: 13 serious, no deaths

6 Oxybutynin: Pediatric Adverse Events 13 reports considered serious –Most common were in patients treated for nocturnal enuresis (unapproved indication) 7 confounded by other drugs/underlying conditions or did not contain enough information to make a causality assessment 6 remaining serious cases –extrapyramidal reaction (unlabeled) in a 10 year old boy –5 remaining serious cases were labeled events that may be due to anticholinergic effects of oxybutynin, particularly anticholinergic CNS excitation (hallucinations, irritability, insomnia).

7 Oxybutynin: Pediatric CNS Excitation (32/114) in pediatric patients vs. (99/1286) in adult reports using preferred terms Preferred Terms indicative of CNS excitation: Abnormal dreams; hallucination; panic reaction; aggression; hallucination, visual; psychomotor hyperactivity; agitation; initial insomnia; restlessness; anger; insomnia, sleep disorder; anxiety; irritability; sleep terror; attention deficit/hyperactivity disorder; middle insomnia; sleep walking; emotional disorder; nervousness; tremor; excitability; panic attack

8 Oxybutynin: Pediatric CNS Excitation May or may not indicate increased sensitivity to anticholinergic effect of this drug in pediatric patients –Anticholinergics may cross the blood-brain barrier in pediatric patients more easily –Cholinesterase levels virtually the same for pediatric patients and adult patients Patients had other underlying neurologic conditions and on other psychoactive drugs

9 Summary: Oxybutynin No safety signal identified: few reports, single cases, confounded or insufficient information The FDA recommends routine monitoring of oxybutynin for AEs in all populations Does the Advisory Committee concur?

10 Acknowledgements OSE Paula Gish Rosemary Johann-Liang PMHS Kristin Phucas DRUP Mark Hirsch